Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Brensocatib (AZD7986) 是一种二肽基肽酶 1 (DPP1) 抑制剂,在人,小鼠,大鼠,狗和兔中的pIC50分别为 6.85, 7.6, 7.7, 7.8 和 7.8。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 689 | 现货 | ||
5 mg | ¥ 1,630 | 现货 | ||
10 mg | ¥ 2,890 | 现货 | ||
25 mg | ¥ 4,780 | 现货 | ||
50 mg | ¥ 6,850 | 现货 | ||
100 mg | ¥ 9,270 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,760 | 现货 |
产品描述 | Brensocatib (AZD7986) is a Dipeptidyl peptidase 1 (DPP1) inhibitor (pIC50s: 6.85, 7.7, 7.6, 7.8, and 7.8 in human, rat, mouse, rabbit, and dog, respectively). |
靶点活性 | DPP1:pIC50: 6.85(human), DPP1:pIC50: 7.6(mouse), DPP1:pIC50: 7.7(rat), DPP1:pIC50: 7.8(dog), DPP1:pIC50: 7.8(rabbit) |
体外活性 | AZD7986在丙醛活性测定中表现稳定,半衰期超过50小时。经AZD7986(38 pM至10 μM)处理后,观察到DPP1及所有三种NSPs(NE、Pr3、CatG)的细胞裂解物酶活性呈浓度依赖性下降。AZD7986以浓度依赖性方式抑制所有三种NSPs的激活,三者的pIC50值均约为7。这种活性降低几乎是完全的,NE、Pr3和CatG的活性在10 μM AZD7986下降至对照的4至10%。 |
体内活性 | AZD7986在血浆中显示出良好的稳定性,半衰期超过10小时。在体内,AZD7986以剂量依赖的方式抑制了骨髓细胞裂解物中的Pr3和NE的激活,但不抑制CatG的激活。 |
激酶实验 | Activation of neutrophil serine proteases is assessed in vitro using primary bone marrow-derived CD34+ neutrophil progenitor cells. Cells are cultured in media supplemented with rhSCF and rhIL-3 for 7 days, and then for a further 7 days in the presence of G-CSF and different concentrations of AZD7986 (38 pM to 10 μM). After harvesting and lysis with 10% Triton X-100 buffer, cell lysates are kept at -20°C until NSP activity analysis. |
细胞实验 | Cellular potency is studied using the DPP1-expressing monocytic U937 cell line. Briefly, cells grown in RPMI are plated on 384-well polypropylene v-bottom plates at a density of 5×10^5 cells/mL per well. Added to this is 10 μL of AZD7986 at 37°C for 60 min, followed by 350 μM Gly-Phe-AFC. The well fluorescence is read using a multilabel plate reader. Data are analyzed to calculate pIC50 values. |
动物实验 | Rats are used for the in vivo study. Naive rats are dosed orally twice daily with AZD7986 at 0.2, 2, and 20 mg/kg/day for 8 days. At termination, bone marrow is taken by femural aspiration for neutrophil serine proteases activity analysis using commercial synthetic peptide substrates. |
别名 | AZD7986, INS 1007 |
分子量 | 420.46 |
分子式 | C23H24N4O4 |
CAS No. | 1802148-05-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: ≥100 mg/mL (237.83 mM)
H2O: Insoluble
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3783 mL | 11.8917 mL | 23.7835 mL | 59.4587 mL |
5 mM | 0.4757 mL | 2.3783 mL | 4.7567 mL | 11.8917 mL | |
10 mM | 0.2378 mL | 1.1892 mL | 2.3783 mL | 5.9459 mL | |
20 mM | 0.1189 mL | 0.5946 mL | 1.1892 mL | 2.9729 mL | |
50 mM | 0.0476 mL | 0.2378 mL | 0.4757 mL | 1.1892 mL | |
100 mM | 0.0238 mL | 0.1189 mL | 0.2378 mL | 0.5946 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Brensocatib 1802148-05-5 Proteases/Proteasome Ubiquitination Proteasome Dipeptidyl Peptidase AZD 7986 AZD-7986 INS1007 DPP inhibit AZD7986 INS 1007 INS-1007 Inhibitor inhibitor